Rockrose (Cistus): Research & Studies

← Back to the Cistus topic overview

What this collection is—and is not

The Cistus literature covers phytochemistry, traditional use, antimicrobial and antiviral in vitro research, several animal models, and a comparatively small number of human studies. The most clinically interesting studies concern upper respiratory tract infections, as well as individual exploratory investigations into oral flora, lipid/oxidation markers, and topical applications.

For this research page, we are deliberately keeping things in perspective: the focus is on human studies, regulatory assessments, and medically relevant preclinical research. The preparation in question is particularly important. A standardized polyphenol-rich specialty extract such as CYSTUS052, a hot-water infusion, an ethyl acetate extract, and the essential oil are chemically and pharmacologically not the same.

How the evidence should be interpreted

Human: Clinical research involving humans. Even randomized studies are only as informative as the preparation, comparator group, sample size, blinding, and reproducibility.

Review / meta-analysis: Summary of existing research. The evidentiary value depends on the quality and comparability of the included studies.

Animal: Experimental animal model. Biological plausibility, but no direct transferability to humans.

Cell: In vitro, cell, or tissue research. Furthest removed from a clinical efficacy claim.

In situ / ex vivo: Investigation in humans or using human-relevant models without a conventional therapeutic endpoint, such as biofilm formation on worn enamel samples. Clinically closer than pure cell culture, but not proof of efficacy for a disease.

Regulatory review: Overall assessment of the available literature by regulatory authorities. Particularly helpful for classifying traditional use, preparation definition, clinical transferability, and gaps in the data.

The major research areas

The clearest human research concerns upper respiratory tract infections. Two studies by Kalus and colleagues examined the standardized extract CYSTUS052. In addition, there is an older open-label observation involving tonsillopharyngitis. These studies provide clinical signals, but they are preparation-specific and cannot automatically be generalized to other rockrose products.

A second major area is basic research into antimicrobial and antiviral effects. Cistus extracts have been studied in vitro against influenza, HIV, filoviruses, SARS-CoV-2 models, oral bacteria, and Borrelia. The results depend heavily on the solvent and fraction. Borrelia is a particularly good example: in one study, lipophilic/volatile fractions were active, while the aqueous extract did not reduce growth.

Further research areas include polyphenols, antioxidant and antiglycative properties, inflammatory signaling pathways, skin models, and cardiometabolic markers. Most of this research is preclinical or exploratory.

Cistus is not always the same—and tea is not an extract

The botanical naming is not entirely consistent in the literature. Studies refer to Cistus incanus, Cistus × incanus, Cistus creticus, or older subspecies/synonym designations. There are also studies on Cistus ladanifer, C. monspeliensis, and other species. For a reliable assessment, it must therefore always be verified which plant was actually studied.

The preparation is just as important. CYSTUS052 is a specialized, polyphenol-rich extract. A water infusion contains a different profile of compounds than ethyl acetate, hexane, or essential oil fractions. Results from a lipophilic Borrelia study therefore cannot, for example, be applied to rockrose tea.

Particularly relevant clinical areas

Respiratory tract infections

The strongest clinical signals come from studies of CYSTUS052 for upper respiratory tract infections. One prospective, randomized, placebo-controlled study with 160 patients and another randomized comparative study with green tea reported more favorable symptom progression with the specialized extract.

In its assessment of Cistus creticus, the EMA explicitly points out that studies involving such specialized branded extracts cannot readily demonstrate the efficacy of the traditional tea preparation. This distinction should remain visible on the public-facing page.

Oral flora and biofilm

A small in situ study with four participants investigated Cistus tea’s effect on initial bacterial adhesion to enamel samples. Other laboratory studies investigated Streptococcus mutans and biofilms. This is a plausible field of research, but the sample size and study design do not permit broad clinical conclusions.

Cardiometabolic markers and oxidative stress

A pilot study of 24 healthy adults investigated Cistus incanus tea for twelve weeks and reported changes in lipid and oxidation markers. Because of the small sample, exploratory nature, and healthy population, no therapeutic conclusion should be drawn from it.

Viruses

Cistus extracts show in vitro activity against several enveloped viruses. Additional mouse data are available for influenza. For HIV, Ebola/Marburg, and SARS-CoV-2, however, the evidence consists predominantly of cell-culture research. These are mechanistically interesting data, but not evidence of clinical efficacy.

A retrospective study of a Cistus creticus-containing nasopharyngeal spray for mild COVID-19 should be given considerably less weight than a controlled clinical study because of its non-randomized design, combination product, and publication setting.

Bacteria, oral microorganisms, and Borrelia

Cistus fractions have been investigated against numerous bacteria. For Borrelia burgdorferi, the essential oil or lipophilic extracts showed clear in vitro activity; in the same study, the aqueous extract did not reduce growth. This difference in particular shows how risky blanket statements such as “Cistus works against Borrelia” would be.

Results against Streptococcus mutans or other microorganisms initially remain in vitro or in situ findings and are not evidence for treating an infection in humans.

Safety

The EMA assessment describes only limited clinical safety data. The available studies did not identify serious safety problems as a typical signal; at the same time, the evidence base is inadequate for rare adverse effects, long-term use, pregnancy, breastfeeding, and children.

Hypersensitivity reactions are generally possible. The sound conclusion is therefore not “proven safe,” but rather: the clinical safety profile to date appears relatively unremarkable, although it is incomplete and product-specific.

Plant matrix and preparation method

For Cistus, the extraction method can completely change the observed activity. Water primarily extracts more hydrophilic polyphenols; ethyl acetate, hexane, or steam distillation capture other, more lipophilic groups of compounds. Essential oil and labdanum data therefore cannot be extrapolated to tea.

Even within aqueous preparations, the polyphenol profile and concentration vary with species, origin, leaf content, particle size, brewing time, and temperature. Standardized specialty extracts may in turn differ substantially in composition from a traditional infusion. For each publication, the specific preparation should therefore be stated directly alongside the study result.

Study overview

The following table contains 30 publications, clinical reports, and key regulatory sources individually recorded to date in this working version. It does not claim to represent every Cistus publication released worldwide. The focus is on human research, clinically relevant preclinical studies, product comparisons, safety, and key reviews. The list can be expanded continuously.